University Medical Center Utrecht
Utrecht, 3584 CX, Netherlands
NCT Number: NCT01293071
The SATURN ICU-trial studies the effect of antibiotic rotation on the prevalence of antibiotic resistant Gram-negative colonisation.
Looking for future studies?
Notify Me10 year and older
All sexes
Interventional
Phase 4
Utrecht, 3584 CX, Netherlands
Antibiotic rotation has been previously studied with varied results. The theory behind antibiotic rotation is that intermittently changing antibiotic classes will reduce the ecological selective pressure that drives the emergence of antibiotic resistance.
This study compares the effect of 2 types of antibiotic rotation on Gram-negative colonisation in the ICU and also compares both interventions with standard care.
The two interventions apply to the empiric treatment and are: 1) "fast" rotation, i.e. every other patient another class and 2) "slow" rotation, i.e. every other 1.5month another preferred class for empiric Gram-negative antibiotic therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ICUs planning to introduce, during the SATURN trial period, any major diagnostic- or intervention program that will affect AMRB ecology*
Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
Other names: Any antibiotic from the local guidelines can be used.
Time frame: Monthly point-prevalence screening of all ICU patients
Time frame: 2011-2013
Time frame: 2011-2013
Time frame: 2011-2013
Time frame: 2011-2013
UMC Utrecht
Other
The SATURN Consortium, "Impact of Specific Antibiotic Therapies on the Prevalence of hUman Host ResistaNt Bacteria". Workpackage 2: The SATURN ICU-trial.
Acronym: SATURN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02505386
Infections
Bordeaux, France
View Trial DetailsNCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT02231879
Agammaglobulinemia, Agranulocytosis
Bethesda, Maryland, United States
View Trial DetailsNCT05180110
Infections, Inflammation
Edinburgh, United Kingdom
View Trial Details